-
FDA Approves Updated Nuvaxovid Vaccine for the 2026-2027 Season
NASDAQ: $NVAX Staying Ahead of COVID-19: The Latest Vaccine Update The landscape of COVID-19 vaccination continues to evolve to provide the most effective protection against circulating variants. Recently, the U.S. Food and Drug Administration (FDA) took a significant step by approving the XBB.1.5-adapted Nuvaxovid vaccine for the upcoming 2026-2027 vaccination season. What You Need to…
-
Updated COVID-19 Protection: FDA Approves New Pfizer-BioNTech Comirnaty Vaccine
NYSE: $PFE A New Development in COVID-19 Prevention As we continue to navigate the evolving landscape of respiratory health, the U.S. Food and Drug Administration (FDA) has taken a significant step forward. Pfizer and BioNTech have officially received FDA approval for their updated Comirnaty COVID-19 vaccine, specifically adapted to target more recent circulating variants. What…
-
Moderna Receives U.S. FDA Approval for Updated 2026-2027 Spikevax and mNEXSPIKE COVID-19 Vaccines
NASDAQ: $MRNA CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for… Source: Read More